Southlake, TX – According to filings with the U.S. Securities and Exchange Commission, Renibus Therapeutics is raising $35,000,000.00 in new funding. Sources indicate as part of senior management Chairman and Chief Executive Officer, Alvaro Guillem played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Renibus Therapeutics

Renibus Therapeutics Inc. (RTI) is a clinical-stage biotech company focused on the development of novel pharmacologic therapies for acute and chronic kidney disease. RTI’s lead product, RBT-1, is a novel pharmacologic intervention that activates the kidney’s natural protective redox signaling pathways, forming a kidney shield.

To learn more about Renibus Therapeutics, visit http://renibus.com/

Contact:
Alvaro Guillem, Chairman and Chief Executive Officer
682-285-1711
aguillem@renibus.com
https://www.linkedin.com/in/al-guillem-3453315/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved